Skip to main
BLTE
BLTE logo

BLTE Stock Forecast & Price Target

BLTE Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Belite Bio Inc. is experiencing positive momentum due to significant clinical trial results, including a statistically significant improvement in best corrected visual acuity (BCVA) in treated patients, indicating the potential effectiveness of its treatments for retinal degeneration diseases. The company has also reported an increased estimated market value of $3.42 billion, demonstrating strong investor interest and confidence in its developmental pipeline. Additionally, the safety database for its drug tinlarebant is expected to expand, particularly with older demographics, which could enhance its regulatory appeal and broaden its market potential in treating STGD1.

Bears say

Belite Bio Inc's stock outlook is negatively impacted by the company's reliance on the successful commercial viability of its treatments, particularly tinlarebant, which faces challenges in transitioning from orphan drug pricing in a larger indication due to anticipated substantial price cuts. The company's financial projections indicate a difficulty in achieving the estimated $3.1 billion revenue after the patent expiration in 2040, amid a cumulative assumed R&D spend of approximately $2.7 billion, further complicating long-term sustainability. Lastly, there is considerable uncertainty regarding the efficacy of ongoing clinical trials, particularly the Phase 3 GARDian trial, where expectations of consistent drug effects are questionable, and potential outcomes reveal a risk of failing to meet primary endpoints if initial drug efficacy diminishes.

BLTE has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Belite Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Belite Bio Inc (BLTE) Forecast

Analysts have given BLTE a Buy based on their latest research and market trends.

According to 4 analysts, BLTE has a Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $166.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $166.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Belite Bio Inc (BLTE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.